Payment overview · 2025
General Payments
$124.54
6 reported records · 5 companies
Healthcare provider profile · identity verified
Mark Christopher Nadaud, DO
Allopathic & Osteopathic Physicians|Family Medicine · GENOA, OH · NPI 1346235710
Verified facts
What the public records show
CMS Open Payments records show Mark Christopher Nadaud, DO received $124.54 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.19 | 37.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.18 | 24.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $17.35 | 13.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.28 | 12.3% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $14.54 | 11.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $124.54 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.19 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $14.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 691 | 188 |
| Carvedilol | Carvedilol | 562 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 465 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 447 | 114 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 419 | 116 |
| Tramadol Hcl | Tramadol Hcl | 375 | 79 |
| Metformin Hcl | Metformin Hcl | 356 | 92 |
| Omeprazole | Omeprazole | 327 | 97 |
| Gabapentin | Gabapentin | 311 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 268 | 64 |
| Losartan Potassium | Losartan Potassium | 264 | 70 |
| Meloxicam | Meloxicam | 236 | 58 |
| Lisinopril | Lisinopril | 225 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 54 |
| Simvastatin | Simvastatin | 185 | 51 |
| Furosemide | Furosemide | 183 | 49 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 171 | 46 |
| Alprazolam | Alprazolam | 168 | 36 |
| Eliquis | Apixaban | 158 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 38 |
| Allopurinol | Allopurinol | 140 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 127 | 30 |
| Sertraline Hcl | Sertraline Hcl | 125 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 42 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 119 | 36 |
| Spironolactone | Spironolactone | 117 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 111 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 33 |
| Glimepiride | Glimepiride | 106 | 31 |
| Prednisone | Prednisone | 105 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 104 | 19 |
| Ibuprofen | Ibuprofen | 103 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 23 |
| Potassium Chloride | Potassium Chloride | 98 | 22 |
| Celecoxib | Celecoxib | 94 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 25 |
| Azithromycin | Azithromycin | 84 | 66 |
| Synthroid | Levothyroxine Sodium | 82 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 20 |
| Famotidine | Famotidine | 74 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 20 |
| Lorazepam | Lorazepam | 69 | 22 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 62 | 14 |
| Trazodone Hcl | Trazodone Hcl | 61 | 11 |
| Clonazepam | Clonazepam | 60 | 17 |
| Donepezil Hcl | Donepezil Hcl | 59 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 17 |
| Diazepam | Diazepam | 54 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 14 |
| Glipizide | Glipizide | 48 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | suppressed |
| Ozempic | Semaglutide | 45 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 16 |
| Benazepril Hcl | Benazepril Hcl | 42 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 41 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Nitroglycerin | Nitroglycerin | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 13 |
| Sucralfate | Sucralfate | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 12 |
| Fluconazole | Fluconazole | 34 | 20 |
| Cilostazol | Cilostazol | 33 | suppressed |
| Finasteride | Finasteride | 33 | 11 |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 14 |
| Methylprednisolone | Methylprednisolone | 27 | 26 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Colchicine | Colchicine | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 12 |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 18 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 17 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 21 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 20 | 16 |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | 11 |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 17 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $124.54 · 6 records | ABBVIE INC. | AFREZZA, AIRSUPRA, JOURNAVX, QULIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error